1. Summary Information
|
Country |
India |
||
|
Company Name |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Principal Name 1 |
Mr. Sanjeev Jain |
|
Status |
Good |
Principal Name 2 |
Mr. Mata Pher Singh |
|
Registration # |
55-125888 |
||
|
Street Address |
304, Mohan Place, LSC, Saraswati Vihar, New Delhi - 110 034, India |
||
|
Established Date |
19.04.2004 |
SIC Code |
-- |
|
Telephone# |
91-11-47511000 |
Business Style 1 |
Manufacturer |
|
Fax # |
91-11-27023256 |
Business Style 2 |
Supplier |
|
Homepage |
Product Name 1 |
Pharmaceutical Machinery |
|
|
# of employees |
Not
Available |
Product Name 2 |
-- |
|
Paid up capital |
Rs.11,750,000/- |
Product Name 3 |
-- |
|
Shareholders |
Directors or relatives of directors -100% |
Banking |
State
Bank of India |
|
Public Limited Corp. |
NO |
Business Period |
8 Years |
|
IPO |
NO |
International Ins. |
- |
|
Public |
NO |
Rating |
A
(58) |
|
Related
Company |
|||
|
Relation
|
Country
|
Company
Name |
CEO |
|
Subsidiaries |
India
|
Corwis Pharmaceuticals Limited |
-- |
|
Note |
- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
1,933,388,000 |
Current Liabilities |
634,057,000 |
|
Inventories |
1,058,686,000 |
Long-term Liabilities |
1,473,486,000
|
|
Fixed Assets |
2,180,096,000 |
Other Liabilities |
339,694,000 |
|
Deferred Assets |
0,000 |
Total Liabilities |
2,447,237,000 |
|
Invest& other Assets |
68,059,000 |
Retained Earnings |
2,781,242,000 |
|
|
|
Net Worth |
2,792,992,000 |
|
Total Assets |
5,240,229,000 |
Total Liab. & Equity |
5,240,229,000 |
|
Total Assets (Previous Year) |
3,927,984,000 |
|
|
|
P/L Statement as of |
31.03.2011 |
(Unit: Indian Rs.) |
|
|
Sales |
5,689,809,000 |
Net Profit |
615,703,000 |
|
Sales(Previous yr) |
4, 109,312,000 |
Net Profit(Prev.yr) |
402,976,000 |
MIRA INFORM REPORT
|
Report Date : |
16.08.2012 |
IDENTIFICATION DETAILS
|
Name : |
AKUMS DRUGS AND PHARMACEUTICALS LIMITED |
|
|
|
|
Registered Office : |
304, Mohan Place, LSC, Saraswati Vihar, New Delhi - 110 034 |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2011 |
|
|
|
|
Date of Incorporation : |
19.04.2004 |
|
|
|
|
Com. Reg. No.: |
55-125888 |
|
|
|
|
Capital Investment / Paid-up Capital : |
Rs.11.750 Millions |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24239DL2004PLC125888 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
DELA13882B |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAECA7090B |
|
|
|
|
Legal Form : |
A Closely held Public Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturer and Supplier of Pharmaceutical Machinery. |
|
|
|
|
No of Employees : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
A (58) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 11000000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having fine track.
Financial positions of the company appears to be sound. Trade relations are
reported as fair. Business is active. Payments are reported to be regular and
as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
EXTERNAL AGENCY RATING
|
Rating Agency Name |
ICRA |
|
Rating |
A ( Long term rating) |
|
Rating Explanation |
Having adequate degree of safety regarding
timely servicing of financial obligation it carry low credit risk. |
|
Date |
May 2012 |
|
Rating Agency Name |
ICRA |
|
Rating |
A1 ( Short term rating) |
|
Rating Explanation |
Having very strong degree of safety
regarding timely payment of financial obligation it carry low credit risk. |
|
Date |
May 2012 |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
LOCATIONS
|
Registered Office / Corporate Office : |
304, Mohan Place, LSC, Saraswati Vihar, New Delhi - 110 034, India |
|
Tel. No.: |
91-11-47511000 (30 lines) |
|
Fax No.: |
91-11-27023256 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Manufacturing Unit I |
19-20-21, Sector-6A, I.I.E., SIDCUL, Ranipur, Haridwar -
249403, Uttarakhand India |
|
Tel. No.: |
91-1334-239220 – 224, 325982, 84, 85,86 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Manufacturing Unit II |
22, Sector-6A, IIE, SIDCUL, Ranipur, Haridwar - 249403 Uttarakhand, India |
|
Tel. No.: |
91-1334-239220 – 224, 325982, 84 ,85, 86 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
|
|
|
Manufacturing Unit III |
2,3,4,5 Sector-6B, IIE, SIDCUL, Ranipur, Haridwar - 249403
Uttarakhand, India |
|
Tel. No.: |
91-1334- 237100 – 104 |
|
Fax No.: |
91-1334-237105 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Manufacturing Unit IV : |
47, Sector 6B, SIDCUL, Ranipur, Haridwar - 249403
Uttarakhand, India |
|
|
|
|
Manufacturing Unit V : |
48, Sector 6B, SIDCUL, Ranipur, Haridwar - 249403
Uttarakhand, India |
|
|
|
|
Manufacturing Unit VI : |
13, Sector – 6A, SIDCUL, Intergrated Industrial Estate
Ranipur, Haridwar – 249403, |
DIRECTORS
As on 10.09.2011
|
Name : |
Mr. Sanjeev Jain |
|
Designation : |
Whole-Time Director |
|
Address : |
E -1052, Saraswati Vihar, Delhi - 110 034, India |
|
Date of Birth : |
11.04.1956 |
|
Qualification : |
MBBS (BIO) MBA |
|
Date of Appointment : |
19.04.2004 |
|
DIN No.: |
00323433 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current designation
of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U74899DL1986PTC025186 |
WELCURE
PHARMACEUTICALS PRIVATE LIMITED |
Director |
21-08-86 |
21-08-86 |
- |
Active |
NO |
|
2 |
U85195DL1987PLC194421 |
A.K.
LABORATORIES LIMITED |
Director |
01-04-93 |
01-04-93 |
01-06-07 |
Active |
NO |
|
3 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Whole-time
director |
01-06-07 |
19-04-04 |
- |
Active |
NO |
|
4 |
L24232RJ1996PLC012418 |
WELCURE DRUGS
AND PHARMACEUTICALS LIMITED (TRANSFER FROM DELHI) |
Whole-time
director |
01-04-05 |
01-04-05 |
01-06-07 |
Active |
NO |
|
5 |
U72900DL2010PLC206414 |
AKUMENTIS
HEALTHCARE LIMITED |
Director |
29-07-10 |
29-07-10 |
14-10-10 |
Active |
NO |
|
Name : |
Mr. Mata Pher Singh |
|
Designation : |
Whole Time Director |
|
Address : |
Plot No. 19, 20, 21 Sector 6A, II, E, SIDCUL, Haridwar – 249 403, |
|
Date of Birth : |
20.06.1957 |
|
Qualification : |
BA LLB |
|
Date of Appointment : |
23.05.2004 |
|
DIN No.: |
00356220 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U99999DL1998PLC095297 |
AMAZING RESEARCH
LABORATORIES LIMITED |
Director |
23-11-01 |
23-11-01 |
21-10-07 |
Active |
NO |
|
2 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Whole-time
director |
01-09-05 |
23-05-04 |
- |
Active |
NO |
|
Name : |
Mr. Sandeep Jain |
|
Designation : |
Whole-Time Director |
|
Address : |
E -1052, Saraswati Vihar, Delhi - 110 034, India |
|
Date of Birth : |
05.08.1967 |
|
Qualification : |
BCom MBA FMSPI AMIMA |
|
Date of Appointment : |
19.04.2004 |
|
DIN No.: |
00323476 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U85195DL1987PLC194421 |
A.K.
LABORATORIES LIMITED |
Director |
01-04-93 |
01-04-93 |
01-06-07 |
Active |
NO |
|
2 |
U74899DL1986PTC025186 |
WELCURE PHARMACEUTICALS
PRIVATE LIMITED |
Director |
04-10-99 |
04-10-99 |
- |
Active |
NO |
|
3 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Whole-time
director |
01-06-07 |
19-04-04 |
- |
Active |
NO |
|
4 |
L24232RJ1996PLC012418 |
WELCURE DRUGS
AND PHARMACEUTICALS LTD. (TRANSFER FROM |
Whole-time
director |
01-08-04 |
01-08-04 |
01-06-07 |
Active |
NO |
|
5 |
U74899DL1994PLC057323 |
MAXCURE DRUGS
AND PHARMACEUTICALS LIMITED |
Additional
director |
02-02-10 |
02-02-10 |
- |
Active |
NO |
|
Name : |
Mr. Narendra Dev Sachdeva |
|
Designation : |
Whole Time
Director |
|
Address : |
40/22, IIIrd Floor, C R Park, Delhi – 110 019, India |
|
Date of Birth : |
15.10.1960 |
|
Qualification : |
B Pharma (Hons) |
|
Date of Appointment : |
27.08.2004 |
|
DIN No: |
00330005 |
|
Name : |
Mr. Santosh Kumar Talwar |
|
Designation : |
Additional Director |
|
Address : |
A 603, Divya Apartment, Sector 10, Plot 21, Dwarka, New Delhi -
110066, India |
|
Date of Birth : |
08.08.1945 |
|
Qualification : |
MSC PHD |
|
Date of Appointment : |
01.06.2008 |
|
DIN No.: |
02103812 |
|
Name : |
Mr. Jitendra Sharma |
|
Designation : |
Additional Director |
|
Address : |
R-Block, 75-G, |
|
Date of Birth : |
20.02.1970 |
|
Qualification : |
BA LLM MBA |
|
Date of Appointment : |
16.01.2011 |
|
DIN No.: |
03329817 |
KEY EXECUTIVES
|
Name : |
Ms. Prerna Suneja |
|
Designation : |
Secretary |
|
Address : |
R Block, 75G, Dilshad Garden, Delhi
- 110095, India |
|
Date of Birth/Age : |
20.10.1984 |
|
Date of Appointment : |
02.03.2010 |
|
PAN no.: |
BRHPS2940A |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 10.09.2011
|
Names of Shareholders |
|
No. of Shares |
|
Sanjeev Jain |
|
478275 |
|
Sanjeev Jain and Sons HUF |
|
22000 |
|
Sanjeev Jain Joint with D C Jain and Sons HUF |
|
85000 |
|
Lata Jain |
|
75 |
|
Sanjeev Jain Joint with Arushi Jain |
|
300 |
|
Lata Jain Joint with Umang Jain |
|
50 |
|
Sanjeev Jain Joint with Kiran Jain |
|
1800 |
|
Sandeep Jain |
|
447425 |
|
Sandeep Jain and Sons HUF |
|
52925 |
|
Sandeep Jain Joint with D.C Jain and Sons HUF |
|
85000 |
|
Sandeep Jain Joint with Kanishk Jain |
|
300 |
|
Manan Jain U/G Sandeep Jain |
|
50 |
|
Sandeep Jain Joint with Kiran Jain |
|
1800 |
|
Total |
|
1175000 |
As on 10.09.2011
|
Equity Share Breakup |
|
Percentage of Holding |
|
Category |
|
|
|
Directors
or relatives of directors |
|
100.00 |
|
Total |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer and Supplier of Pharmaceutical Machinery. |
||||
|
|
|
||||
|
Products: |
Pharmaceutical Machinery |
PRODUCTION STATUS
As on 31.03.2010
|
Particulars |
Unit |
Licensed
Capacity |
Installed
Capacity |
Actual
Production |
|
Tablets |
Nos. In Crs. |
N.A. |
2884.00 |
385.20 |
|
Capsule |
Nos. In Crs. |
N.A. |
555.00 |
88.87 |
|
Dry Syrups |
Nos. In Crs. |
N.A. |
24.00 |
1.11 |
|
Liquid Oral |
Kilo Liters |
N.A. |
28080.00 |
1198.00 |
|
Dry Powder Injection |
Nos. In Crs. |
N.A. |
24.88 |
1.87 |
|
Liquid Injection |
Nos. In Crs. |
N.A. |
82.88 |
7.13 |
|
Eye/Ear Drops (SVP) |
Nos. In Crs. |
N.A. |
10.80 |
2.81 |
|
Infusion Bottles (LVP) |
Nos. In Crs. |
N.A. |
2.99 |
1.17 |
|
Cosmetics products |
M.T. |
N.A. |
5904.00 |
41(Kgs) |
GENERAL INFORMATION
|
Customers : |
· ABBOTT India Limited · Cipla Limited · Alembic Limited · Blue Cross Laboratories Limited · FDC Limited · INTAS Pharmaceuticals Limited · Lupin Limited · Mankind Pharma Private Limited · Micro Labs Limited · Orchid Healthcare · Modi Mundi · Venus Remedies Limited · Shreya Life Science Private Limited · Wockhardt Limited · Sun Pharmaceuticals Industries Limited · Piramal Healthcare Limited · Emucure Pharmaceuticals Limited · Aventis Pharma Limited · Cadila Pharmaceuticals Limited · Alkem Laboratories Limited · Plethico Pharmaceuticals Limited · TTK Healthcare Limited · Biochem Pharmaceuticals Industries Limited · IPCA Laboratores Limited · Zydus Cadila Healthcare Limited · J. B. Chemicals and Pharmaceuticals Limited · Indoco Remedies Limited · Flamingo Pharmaceuticals Limited · Kee Pharma Limited · Pharmed Limited · Panacea Biotec · Ajanta Pharma Limited · Cosme Pharma Laboratories Limited ·
Sunways · Torrent Pharmaceuticals Limited · Win Medicare · Vegapharm · Aventis · Europa Healthcare Limited |
|||||||||||||||
|
|
|
|||||||||||||||
|
No. of Employees : |
Not Available |
|||||||||||||||
|
|
|
|||||||||||||||
|
Bankers : |
· State Bank of India, 2nd Floor, MID Corporate Loan administration Unit, Chandni Chowk, Delhi – 110052, India · ICICI Bank Limited, Land Mark Race Cource Circle, Alkapuri, Baroda – 390 015, Gujarat, India · Standard Chartered Bank, Credit Risk Control, Narain Manzil, 23 Barakhamba Road, New Delhi-110001, Delhi, India ·
State Bank of |
|||||||||||||||
|
|
|
|||||||||||||||
|
Facilities : |
Footnotes (A) Term Loan
from SBI (Secured by way of a first charge against all immovable and movable assets
of the company, both present and future and personal guarantee) Term Loan
from ICICI (Secured by way of a pari passu charge against all immovable and
movable assets of Unit-II and Unit-III of the company, both present and
future and personal guarantee) Term Loan from Standard Chartered Bank
(Secured by way of a first charge against all immovable and movable assets of
Unit-IV and V, both present and future and personal guarantee) (B) Term Loan
from SBI (Secured by way of a first charge against all immovable and movable
assets of the company, both present and future and personal guarantee) Term
Loan from ICICI (Secured by way of a pari passu charge against all immovable
and movable assets of Unit-II and Unit-III of the company, both present and
future and personal guarantee) Term Loan from Standard Chartered Bank
(Secured by way of a first charge against all immovable and movable assets of
Unit-IV and V, both present and future and personal guarantee) (C) Bank
Borrowings for working capital (Cash Credit from SBI-secured by Hypothecation
of stocks, book debts and fixed and movable assets; equitable mortgage by
deposit of title deeds in respect of land at Haridwar and personal guarantee)
Bank Borrowings for working capital (Cash Credit from Standard Chartered
Bank-secured by Hypothecation/mortgage of stocks, book debts and fixed and
movable assets of unit IV and V and personal guarantee) (D) Bank Borrowings for working capital (Cash Credit from SBI-secured
by Hypothecation of stocks, book debts and fixed and movable assets;
equitable mortgage by deposit of title deeds in respect of land at Haridwar
and personal guarantee) Bank Borrowings for working capital (Cash Credit from
Standard Chartered Bank-secured by Hypothecation/mortgage of stocks, book
debts and fixed and movable assets of unit IV and V and personal guarantee) |
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Anil Jain D.D and Company Chartered Accountants |
|
Address : |
611, Surya Kiran Building, 19 Kasturba Gandhi Marg, New Delhi -110
001, India |
|
Tel. No.: |
91-11-23765494/23765495 |
|
PAN No.: |
AAIPJ1313K |
|
|
|
|
Subsidiaries : |
CIN No.: U24230DL2006PLC147642
CIN No.: U99999DL1998PLC095297
CIN No.: U24232DL2008PLC185686
CIN No.: U24232DL2009PLC186841
CIN No.: U72900DL2010PLC206414
CIN No.: U74899DL1994PLC057323 |
CAPITAL STRUCTURE
As On 31.03.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
1200000 |
Equity Shares |
Rs.10/- each |
Rs.12.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
1175000 |
Equity Shares |
Rs.10/- each |
Rs.11.750
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
11.750 |
11.750 |
11.750 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
2781.242 |
2165.538 |
1762.562 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
2792.992 |
2177.288 |
1774.312 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
1473.486 |
912.451 |
947.393 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
1473.486 |
912.451 |
947.393 |
|
|
DEFERRED TAX LIABILITIES |
171.276 |
123.166 |
86.992 |
|
|
|
|
|
|
|
|
TOTAL |
4437.754 |
3212.905 |
2808.697 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
2180.096 |
1778.659 |
1490.230 |
|
|
Capital work-in-progress |
61.909 |
3.668 |
18.331 |
|
|
|
|
|
|
|
|
INVESTMENT |
6.150 |
5.650 |
4.250 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
1058.686
|
740.856
|
604.662
|
|
|
Sundry Debtors |
1054.084
|
971.172
|
909.072
|
|
|
Cash & Bank Balances |
62.142
|
55.848
|
95.177
|
|
|
Other Current Assets |
0.000
|
0.000
|
0.000
|
|
|
Loans & Advances |
817.162
|
372.131
|
271.835
|
|
Total
Current Assets |
2992.074
|
2140.007
|
1880.746
|
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
457.152
|
540.839
|
461.943
|
|
|
Other Current Liabilities |
176.905
|
76.636
|
61.601
|
|
|
Provisions |
168.418
|
97.604
|
61.316
|
|
Total
Current Liabilities |
802.475
|
715.079
|
584.860
|
|
|
Net Current Assets |
2189.599
|
1424.928
|
1295.886
|
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
4437.754 |
3212.905 |
2808.697 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
5689.809 |
4109.312 |
3774.502 |
|
|
|
Other Income |
78.119 |
80.906 |
58.646 |
|
|
|
TOTAL (A) |
5767.928 |
4190.218 |
3833.148 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Consumption materials changes inventories |
4015.669 |
2987.377 |
|
|
|
|
Manufacturing service costs |
181.937 |
133.719 |
|
|
|
|
Employee related expenses |
489.307 |
317.391 |
|
|
|
|
Administrative selling other expenses |
110.915 |
79.196 |
|
|
|
|
TOTAL (B) |
4797.828 |
3517.683 |
3168.088 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
970.100 |
672.535 |
665.060 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
91.666 |
65.328 |
112.817 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
878.434 |
607.207 |
552.243 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
89.339 |
72.808 |
64.247 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
789.095 |
534.396 |
487.996 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
173.392 |
131.420 |
51.761 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
615.703 |
402.976 |
436.235 |
|
|
|
|
|
|
|
|
|
Add |
BALANCE
CARRIED TO THE B/S |
615.703 |
402.976 |
420.205 |
|
|
|
|
|
|
|
|
|
|
TOTAL EARNINGS IN
FOREIGN CURRENCY |
NA |
28.900 |
51.732 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
524.00 |
342.96 |
371.26 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
PAT / Total Income |
(%) |
10.67
|
9.62
|
11.38
|
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
13.87
|
13.00
|
12.93
|
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
15.26
|
13.64
|
14.48
|
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.28
|
0.25
|
0.27
|
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
0.81
|
0.74
|
0.86
|
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
3.73
|
2.99
|
3.21
|
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info Agents |
Available in Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
No |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
No |
|
9] |
Name of person contacted |
No |
|
10] |
Designation of contact person |
No |
|
11] |
Turnover of firm for last three years |
Yes |
|
12] |
Profitability for last three years |
Yes |
|
13] |
Reasons for variation <> 20% |
-- |
|
14] |
Estimation for coming financial year |
No |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister concerns |
Yes |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
Yes |
|
19] |
Payments terms |
No |
|
20] |
Export / Import details (if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm / promoter involved in |
-- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if applicable |
Yes |
|
29] |
Last accounts filed at ROC |
Yes |
|
30] |
Major Shareholders, if available |
Yes |
|
31] |
Date of Birth of Proprietor/Partner/Director, if available |
Yes |
|
32] |
PAN of Proprietor/Partner/Director, if available |
No |
|
33] |
Voter ID No of Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating, if available |
Yes |
BANKERS CHARGES
REPORT AS PER REGISTRY
|
Corporate
identity number of the company |
U24239DL2004PLC125888 |
|
Name of the
company |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
|
Address of the registered
office or of the principal place of
business in |
304, Email Id : legal@akums.net |
|
This form is for |
Modification
of charge |
|
Charge
identification (ID) number of the charge to be modified |
10019466 |
|
Type of charge |
|
|
Particular of
charge holder |
State bank of Email Id :
pandevijay@yahoo.co.in |
|
Nature of
instrument creating charge |
Sanction Letter
reducing interest rate of Fund Based Working Capital Llimit Letter regarding
the grant of Individual Limits within the overall limit |
|
Date of
instrument Creating the charge |
22.10.2011 |
|
Amount secured by
the charge |
Rs.1250.000
Millions |
|
Brief of the principal
terms an conditions and extent and operation of the charge |
Rate of interest Interest CC @ 3%
above Base Rate i.e. present effective rate being 13.00% p.a. with monthly
rests. SLC @ 4% above
Base Rate i.e present effective rate being 14.00% p.a. with monthly rests. Terms of
Repayment As per agreement. Margin Raw
Materials-25%, Finished good-25%, Stock in process-25%, Book
Debts/receivables (upto 90 days)- 25% and Letter of credit and BG -20%. Extent and operation of the charge 100% Others The above is to
secure the credit facilities of Rs.1250.000 Millions i.e. CC (Stocks)
Rs.1000.000 Millions with CC(B/D) sub limit within CC(Stock) (Rs.600.000
Millions), LC of Rs.100.000 Millions,
BG Rs.100.000 Millions and SLC Rs.50.000 Millions, granted by the Bank
to the company. |
|
Short particulars
of the property or asset(s) charged (including complete address and location
of the property) |
Primary Security:
WC : (i) First charge over the current assets at company's head office units I,
II and III including stocks and receivables both present and future. However,
first charge over the current assets of unit IV is with SCB. Collateral
Security: (i) Extension of charge on the fixed assets of the company both
present and future including Equitable Mortgage of factory land and building
situated at (a) Plot No.
19,20,21, Sector-6A, IIE, Ranipur, Haridwar, (b) Plot No. 22,
Sector-6A, IIE, Ranipur, Haridwar, (c) Plot No.
2,3,4 and 5, Sector-6B, IIE, Ranipur, Haridwar, Uttarakhand, India |
|
Date of
instrument modifying the charge |
27.01.2011 |
|
Particulars of
the present modification |
Reduction in Bank
Interest rate from 4% to 3% above Base Rate. The present effective rate being
13% p.a. with monthly rests. |
Fixed Assets:
¨
¨ Building
¨ Plant And Machinery
¨ Electrical Installation
¨ R And D And Laboratory Equipments
¨ Pollution Control Equipment
¨ Office Equipments
¨ Furniture and Fixtures
¨ Vehicles
As Per Website Details:
Board of Directors
MR. SANJEEV JAIN
Mr. Sanjeev Jain, an MBA and has approximately
26 years of experience in the field of sales and marketing of pharmaceuticals.
Mr. Sanjeev Jain had been awarded order of Merit for Management and honored as
Samaj Shree for his services rendered to the public. He is Honorary Secretary
of Federation of Pharmaceutical Enterprise (FOP E).
He is Promoter Director of the Company. He has
been instrumental in setting up the Company. He combines in himself dynamism,
dedication, diligence, devotion, determination, discipline and direction. Under
his dynamic leadership and professional approach, the Company made several
national and foreign collaboration agreements and reached new heights of
growth. His innovative ideas in new product development and patents and
creation and retention of customers have brought company to this level.
MR. SANDEEP JAIN
Mr. Sandeep Jain, B. Com., M.B.A., F.M.S.P.I.,
A.M.I.M.A, is a self-made industrialist with nearly 26 years of matured
experience in the field of Pharmaceuticals specially the production, quality
assurance arid project management.
Mr. Sandeep Jain had been a sitting member of
the Managing Committee of the PHD Chamber and its various Committees. He is
actively associated with many trade and commercial organisations. He had been
Joint Secretary of Rajasthan Pharmaceutical Manufacturers Association; and
Executive Member and Vice-President of Bhiwadi Manufacturers Association. He is
presently the President of Chamber of Devbhumi Phanna industries, Haridwar
Vice-President of SIDCUL Manufacturers Association, Haridwar.
He has been awarded several prestigious awards
like Gold Medal for Management
Order for Merit Award, Samaj Mr. Award for
Excellence in Management, Outstanding Personalities award 1998, Man of the Year
1999 award in recognition of his outstanding contribution to industrial growth,
social commitment and excellence in his field of activity, and Quality Award by
1PER.
Mr. Sandeep Jain is a promoter Director of the
Company. With his strenuous efforts the Company received various National and
International Recognitions and Quality Certificates.
DR. SANTOSH K. TALWAR
Dr, Talwar, MSc., Ph D and Fellow of
Institution of Chemists, Calcutta, Indian Chemical Society Calcutta, Division of
Drug Chemistry, FDA Washington, National Center for Drugs Analysis St. Louis and WHO
Collaborating Center of Chemical Reference Substances Solna, Sweden; is an
Independent Director of the Company.
Dr. Santosh K. Talwar had retired as Director
of Central Indian Pharmacopoeia Laboratory (CIPL),
He also has professional experience as WHO
Consultant and had been working in Regional Drugs Testing Laboratory,
Chandigarh, National Institute of Pharmaceutical Education and Research,
Mohali. He has to his credit many publications and research papers.
Dr. Talwar has core competence in quality
assurance/control principles in drugs and pharmaceuticals, protocol development
of new molecules, Impurity Profiling, Method Development and Validation as per
ICH guidelines, lab designing, equipping up and operationalising as per cGLP
norms.
He is an Acknowledged technical auditor under
cGMP/cGLP/GCP regime and is an expert faculty in all aspects of pharmaceutical
analysis including techniques, practices, methods and pharmacopoeial related
issues.
Mr. N.D. Sachdeva, B. Pharma (Hons.) has more
than 35 years of experience in Drug Manufacturing Operations, Quality Control
and Quality Assurance. He has vast practical exposure of various sections of
pharmaceutical industry such as Tablets, Syrups, Capsules, Ointment and external
applications etc. He is a manufacturing chemist from the Drugs Control
Department, NCT Delhi.
Mr. N.D. Sachdeva is a Whole-time Director of
the company and he looks after the day to day affairs of the factory of the
company including Production and quality controls; development implementation
and maintenance of systems, procedures and records for Quality Management
System, GMP norms, Standard Operating
Procedures, Work Instructions; etc
He is also looking after the Compliance
relating to Drugs and Cosmetics Act, 1940 and other Rules, Notifications,
Circulars etc.; Drugs Licensing, products approval and liaisoning with the
Drugs Department(s).
MR. M.P. SINGH
Mr. M.P. Singh, BA, LL.B. and a Diploma Holder
in Personnel Management is Whole Time Director of the Company. He has nearly
Twenty six years experience in factory management and Personnel or General
Management; which experience includes more than eight years of experience in
Pharmaceutical Companies.
Mr. M.P. Singh looks after the day-to-day
Legal Affairs, General Administration and Management, Personnel Matters and
Commercial Matters of company's factory including matters related to Factories
Act, Labour Laws, Pollution Control and liaison with Government offices.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government official
or a family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.64 |
|
|
1 |
Rs.87.31 |
|
Euro |
1 |
Rs.68.81 |
INFORMATION DETAILS
|
Report Prepared
by : |
VRN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILIRY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
58 |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.